{"entity":{"id":"acerand-therapeutics","kind":"company","name":"Acerand Therapeutics","aka":["优领医药"],"tldr":"Acerand Therapeutics develops small-molecule cancer medicines. Its programmes include ACE-232, a tablet that blocks the CYP11A1 enzyme at the start of steroid hormone production, in an early trial for prostate cancer that no longer responds to hormone therapy, and a selective PARP1 inhibitor.","summary":"Acerand Therapeutics lists addresses in Shanghai and Carmel, Indiana, and says it concentrates its drug discovery on oncology small molecules; its site says it was founded by industry veterans with LAV. ACE-232 is a CYP11A1 inhibitor: the FDA cleared it for clinical investigation in January 2025, the first-in-human phase 1 trial NCT06801236 in metastatic castration-resistant prostate cancer (given with dexamethasone and fludrocortisone, at US and Chinese sites) began in 2025, and China's CDE cleared a study in July 2025. The company also reported first patient enrolment in a phase 1/2 trial of a selective PARP1 inhibitor in March 2024 and preliminary clinical data in May 2025, and an update on ACE-106 in April 2026. Its first cancer trial registered under the sponsor name Acerand Therapeutics (Hong Kong) Limited, NCT06801236, was posted on ClinicalTrials.gov in January 2025.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.acerand.com/"},{"label":"Acerand Therapeutics news","url":"https://www.acerand.com/news.html"},{"label":"ClinicalTrials.gov: phase 1 trial of ACE-232 in mCRPC (NCT06801236)","url":"https://clinicaltrials.gov/study/NCT06801236"}],"tags":[],"related":[],"cancers":["prostate-mcrpc"],"sections":["targeted-therapy","hormonal"],"technologies":["parp-inhibitor"],"targets":["cyp11a1","parp"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website (footer reads 2021).","No financing amounts are stated on the company website; LAV is not explained there, so no investor is listed.","The pipeline page is an image and was not read; ACE-106's target is not recorded.","Company website and news page read on 29 October 2026."],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.acerand.com/","stage":"growth","investors":[],"funding":[]},"route":"/companies/acerand-therapeutics/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"}],"section":[{"id":"hormonal","kind":"section","name":"Hormonal Therapy","route":"/fronts/hormonal/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"}],"target":[{"id":"cyp11a1","kind":"target","name":"CYP11A1 (cholesterol side-chain cleavage enzyme)","route":"/targets/cyp11a1/"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}]}}